Abstract Background In the Tunisian population, as yet a limited number of BRCA1/2
germline mutations have been reported in hereditary breast and/or ovarian cancer. These …

Background Pathogenic BRCA1 founder mutations (c. 4035delA, c. 5266dupC) contribute to
3.77% of all consecutive primary breast cancers and 9.9% of all consecutive primary ovarian …

Germline mutations in the BRCA1 and BRCA2 genes predispose women to breast and
ovarian cancer. An incidence of 5% and 3.3% respectively has been reported of BRCA1 and …

Purpose To evaluate the proportion of Korean ovarian cancer patients with a strong family
history and the genetic status in such patients. Methods and patients Pedigree analysis and …

Purpose Unclassified variants (UVs) of BRCA1 and BRCA2 genes are not defined as
pathogenic for breast cancer, and their clinical significance currently remains undefined …

Distribution and prevalence of germline mutations in BRCA1 and BRCA2 differ among
different populations. For the Turkish population, several studies have addressed high-risk …

Background: About 10,000 women are diagnosed with breast cancer and about 2000
women are diagnosed with ovarian cancer each year in Romania. There is an insufficient …

Background Pathogenic variation in BRCA1 and BRCA2 (BRCA) is one of the most frequent
genetic predispositions for hereditary breast cancer. The identification of the variant carriers …

Mutations in BRCA1 and BRCA2 significantly elevate the risk of developing breast and
ovarian cancer. Limited data exists regarding the prevalence of BRCA mutations, and …

BACKGROUND The contribution of BRCA1 and BRCA2 to ovarian cancer in Japanese
patients is still unclear. This study investigated the frequency of germline mutations in …